Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

57
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
57
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

40
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1...
40
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.4K
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

13
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
13
T Cell Types and Functions01:24

T Cell Types and Functions

3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

19
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
19

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determinants of Infant Participation and Non-Participation in Primary Prevention Trials.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2026
Same author

Integrated transcriptomic and TCR profiling reveals local immune dysregulation of T cells in Gl aGvHD.

Bone marrow transplantation·2026
Same author

Screening Children for Early-Stage Type 1 Diabetes.

JAMA·2026
Same author

Psychosocial implications, acceptability and ethics of screening for paediatric type 1 diabetes: a systematic review and mixed methods evidence synthesis.

Diabetologia·2026
Same author

Continuous glucose monitoring as a tool in early-stage type 1 diabetes.

Diabetologia·2026
Same author

Comparison of IA-2 Bridge ELISA and Radiobinding Assays for Progression Risk Assessment in Early-Stage Type 1 Diabetes.

Diabetes, obesity & metabolism·2026

Related Experiment Video

Updated: Apr 27, 2026

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
06:27

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

16.3K

Interleukin-7 and type 1 diabetes.

Paolo Monti1, Ezio Bonifacio

  • 1Diabetes Research Institute (DRI), IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy, paolo.monti@hsr.it.

Current Diabetes Reports
|July 6, 2014
PubMed
Summary
This summary is machine-generated.

Interleukin-7 (IL-7) drives T-cell proliferation in Type 1 diabetes, exacerbating beta-cell autoimmunity. Targeting the IL-7/IL-7R pathway offers a promising immunotherapeutic strategy for controlling this autoimmune disease.

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.3K
Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

2.1K

Related Experiment Videos

Last Updated: Apr 27, 2026

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
06:27

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

16.3K
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.3K
Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

2.1K

Area of Science:

  • Immunology
  • Endocrinology
  • Autoimmunity

Background:

  • Type 1 diabetes involves T-cells destroying insulin-producing beta cells.
  • Current immunotherapies to protect beta cells have limited success.
  • Understanding T-cell differentiation mechanisms is crucial for developing better treatments.

Purpose of the Study:

  • To review recent evidence on the role of Interleukin-7 (IL-7) in Type 1 diabetes pathogenesis.
  • To explore the rationale for targeting the IL-7/IL-7R axis in immunotherapies.

Main Methods:

  • Review of recent scientific literature and findings.
  • Discussion of T-cell differentiation and expansion mechanisms.
  • Analysis of the impact of homeostatic cytokine IL-7.

Main Results:

  • Autoreactive T-cell differentiation and expansion are promoted by IL-7.
  • IL-7 mediated T-cell proliferation contributes to Type 1 diabetes pathogenesis.
  • The IL-7/IL-7R axis is a key pathway in beta-cell autoimmunity.

Conclusions:

  • IL-7 plays a significant role in the progression of Type 1 diabetes.
  • Targeting the IL-7/IL-7R axis is a viable immunotherapeutic strategy.
  • Novel immunomodulatory approaches should consider the IL-7 pathway to control beta-cell autoimmunity.